Baylor Scott & White Charles A. Sammons Cancer Center | Strategic Alliance Partners

Baylor Scott & White Charles A. Sammons Cancer Center – Dallas and Baylor Scott & White T. Boone Pickens Cancer Hospital make up one of the largest cancer treatment centers in the U.S. As a destination cancer center in immunotherapy and backed by the resources of Texas’ largest not-for-profit healthcare system, we offer innovative, comprehensive and personalized cancer care plans tailored to each patient’s unique needs. From highly specialized programs based on type of cancer to forward-thinking clinical trials to a holistic approach to healing, we are with our patients along every step of their journey no matter how challenging the road becomes.

Latest from Baylor Scott & White Charles A. Sammons Cancer Center


Dr. Kelly on the Benefit of Immunotherapy in Stage III NSCLC

May 02, 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott & White Health's North Texas Cancer Centers and director of oncology at the Baylor Charles A. Sammons Cancer Center on the campus of Baylor University Medical Center, discusses the benefit of immunotherapy in patients with stage III non–small cell lung cancer (NSCLC).

Dr. Konduri Discusses Promise of NGS Testing in NSCLC

May 01, 2019

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses the promise of next-generation sequencing testing in patients with non–small cell lung cancer.

Dr. Nadler Discusses Role of PD-L1 in Squamous NSCLC

April 29, 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the role of PD-L1 in patients with squamous non–small cell lung cancer.

Dr. Konduri on Treatment Options for Patients With EGFR-Mutant NSCLC

April 24, 2019

Kartik Konduri, MD, medical director, Chest Cancer Research and Treatment Center, Baylor Charles A. Sammons Cancer Center, Baylor Scott & White Health, discusses treatment options available for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Konduri on Sequencing Therapy in EGFR+ NSCLC

April 18, 2019

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, on the campus of Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer.

Dr. Rimawi Discusses KATHERINE Trial in HER2+ Breast Cancer

January 19, 2019

Mothaffar F. Rimawi, MD, an associate professor and director of Clinical Research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the KATHERINE trial in HER2-positive breast cancer.

Dr. Paulson Discusses Unmet Needs in the Treatment of NETs

September 27, 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.

Dr. Paulson Discusses the Current Treatment for NETs

September 05, 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses the current treatment of patients with neuroendocrine tumors.

Expert Discusses Finding the Optimal Treatment Strategy in CRC

August 25, 2018

A. David McCollum, MD, discusses the need for greater use of molecular profiling, the importance of tumor sidedness when selecting a treatment regimen, and the value of maintenance therapy in patients with metastatic disease.